Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers
JA Doshi, JT Puckett, MS Parmacek… - … Quality and Outcomes, 2018 - Am Heart Assoc
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an
innovative treatment option for patients with familial hypercholesterolemia or clinical …
innovative treatment option for patients with familial hypercholesterolemia or clinical …
Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel
class of medications for patients with familial hypercholesterolemia or clinical atherosclerotic …
class of medications for patients with familial hypercholesterolemia or clinical atherosclerotic …
A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model
D McCormick, DL Bhatt, HE Bays, PR Taub… - Journal of managed …, 2020 - jmcp.org
BACKGROUND: Multiple barriers exist for appropriate use of the proprotein convertase
subtilisin/kexin type 9 enzyme inhibitors (PCSK9i) in patients with atherosclerotic …
subtilisin/kexin type 9 enzyme inhibitors (PCSK9i) in patients with atherosclerotic …
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates
VW Reynolds, ME Chinn, JA Jolly, TN Kelley… - Journal of Clinical …, 2019 - Elsevier
Background Access to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors that
lower low-density lipoprotein cholesterol in patients at high risk of atherosclerotic …
lower low-density lipoprotein cholesterol in patients at high risk of atherosclerotic …
[HTML][HTML] Prescribing patterns of proprotein convertase subtilisin-kexin type 9 inhibitors in eligible patients with clinical atherosclerotic cardiovascular disease or …
DG Karalis, UG Mallya, AF Ghannam, J Elassal… - The American journal of …, 2018 - Elsevier
Two proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are approved for
patients with atherosclerotic cardiovascular disease or heterozygous familial …
patients with atherosclerotic cardiovascular disease or heterozygous familial …
Trends in PCSK9 inhibitor prescriptions before and after the price reduction in patients with atherosclerotic cardiovascular disease
A Smith, D Johnson, J Banks, SW Keith… - Journal of Clinical …, 2021 - mdpi.com
Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-
density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high …
density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high …
Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes
KD Myers, N Farboodi, M Mwamburi… - … Quality and Outcomes, 2019 - Am Heart Assoc
Background: Atherosclerotic cardiovascular disease remains a major cause of death and
disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i …
disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i …
Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study
Background The FOURIER (Further Cardiovascular Outcomes Research With PCSK9i
Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors in Subjects With Elevated Risk) …
Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors in Subjects With Elevated Risk) …
Association between industry marketing payments and prescriptions for PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in the United States
Background: Marketing payments from the pharmaceutical industry to physicians have come
under scrutiny due to their potential to influence clinical decision-making. Two proprotein …
under scrutiny due to their potential to influence clinical decision-making. Two proprotein …
Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors
PB Rane, J Patel, DJ Harrison, J Shepherd… - American Journal of …, 2018 - Springer
Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce low-
density lipoprotein cholesterol (LDL-C) levels and are approved for patients with familial …
density lipoprotein cholesterol (LDL-C) levels and are approved for patients with familial …